The impact of carbapenemases on antimicrobial development and therapy

Current Opinion in Investigational Drugs

Volumn 3, Issue 2, 2002, Pages 218-224

  Livermore, David M ^a  

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

Author keywords

lactams; Acinetobacter; Carbapenemases; Metalloenzyme; Pseudomonas

Indexed keywords

6 (1 HYDROXYETHYL) 4 METHYL 3 [5 (4 METHYLAMINOMETHYLPHENYL) 3 PYRROLIDINYLTHIO] 7 OXO 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CARBAPENEMASE INHIBITOR; ENZYME INHIBITOR; INOSINE PHOSPHATE; ISEPAMICIN; MINOCYCLINE; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SUCCINIC ACID DERIVATIVE; SULBACTAM; THIAZOLIDINE DERIVATIVE; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIUM ISOLATE; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG HALF LIFE; DRUG TARGETING; DRUG USE; ENTEROBACTERIACEAE; ENZYME INHIBITION; EPIDEMIC; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION; INHIBITION KINETICS; NONHUMAN; PRESCRIPTION; PSEUDOMONAS; REVIEW; SPECIES DIFFERENCE; UNITED STATES;

ACINETOBACTER; ACINETOBACTER INFECTIONS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; ENZYME INHIBITORS; GENES, BACTERIAL; HUMANS; RECOMBINATION, GENETIC;

EID: 0036229974     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the loss of an outer membrane protein
2. Carbapenem-hydrolyzing β-lactamases
3. Nosocomial infection caused by Xanthomonas maltophilia: A case-control study of predisposing factors
4. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen
5. Comparison of treatment with imipenem versus ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: A historical cohort study
6. Infections caused by Stenotrophomonas maltophilia - A prospective study
7. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens
8. Transferable imipenem resistance in Pseudomonas aeruginosa
9. Carbapenem-hydrolysing IMP-1 β-lactamase in Klebsiella pneumoniae from Singapore
10. IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the United Kingdom
11. Identification of a plasmid encoding SHV-12, TEM-1, and a variant of IMP-2 metallo-β-lactamase, IMP-8, from a clinical isolate of Klebsiella pneumoniae
12. IMP allelic variants carried by gene cassettes of different phylogeny
13. Amino acid substitutions in a variant of IMP-1 metallo-β-lactamase
14. IMP-4, a novel metallo-β-lactamase from nosocomial Acinetobacter spp collected in Hong Kong between 1994 and 1998
15. Occurrence of a new metallo-β-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China
16. Plasmid-encoded metallo-β-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem
17. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa
18. Appearance and dissemination of a novel transferable IMP-9 metallo-β-lactamase in P. aeruginosa strains from Guangzhou, PRC
19. VIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate
20. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France
21. Sequence analysis of ARI-1, a novel OXA β-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92
22. OXA-24, a novel class D β-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain
23. Characterization of: OXA-25, OXA-26, and OXA-27, molecular Class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii
24. Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina
25. Limitation of Acinetobacter baumannii treatment by plasmid-mediated carbapenemase ARI-2
26. Oxacillin-hydrolyzing β-lactamase involved in resistance to imipenem in Acinetobacter baumannii
27. Biochemical characterization of a β-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates
28. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A β-lactamase, Sme-1, from Serratia marcescens S6
29. SME-type carbapenem-hydrolyzing class A β-lactamases from geographically diverse Serratia marcescens strains
30. Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa
31. Characterization of IMI-1 β-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae
32. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae
33. Klebsiella pneumoniae (KP) isolates producing a carbapenem hydrolyzing enzyme (CHE)
34. Outbreak of infections caused by Klebsiella pneumoniae producing a novel carbapenem-hydrolysing Class A β-lactamase, KPC-3
35. Metallo-β-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme
36. Transferable imipenem-resistance in Acinetobacter species from a clinical source
37. Biochemical properties of a carbapenem-hydrolyzing β-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli
38. Of Pseudomonas, porins, pumps and carbapenems
39. Antimicrobial susceptibility of Pseudomonas aeruginosa: Results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test
40. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa, our worst nightmare?
41. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems
42. Three-year surveillance study of nosocomial bacterial resistance in Argentina. The Antimicrobial Committee; And the National Surveillance Program (SIR) Participants Group
43. Antibiotic resistance among clinical isolates of acinetobacter in the United Kingdom and in-vitro evaluation of tigecycline (GAR-936)
44. Carbapenem-resistant Klebsiella pnuemoniae in Singapore producing IMP-1 β-lactamase and lacking an outer membrane protein
45. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in A baumannii is not due solely to the presence of β-lactamases
46. Molecular characterization of an enterobacterial metallo β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance
47. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece
48. PCR-based DNA fingerprinting (REP-PCR, AP-PCR) and pulsed-field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant Acinetobacter baumannii
49. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii
50. IMP
51. Emerging strategies in infectious diseases: New carbapenem and trinem antibacterial agents
52. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia
53. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent β-lactamases
54. Inhibition of IMP-1 metallo-β-lactamase and sensitization of IMP-1-producing bacteria by thioester derivatives
55. Inhibition of metallo-β-lactamases by a series of mercaptoacetic acid thiol ester derivatives
56. Crystal structure of the IMP-1 metallo β-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: Binding determinants of a potent, broad-spectrum inhibitor
57. Carbapenem derivatives as potential inhibitors of various β-lactamases, including class B metallo-β-lactamases
58. Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-β-lactamase
59. 2+ metallo-β-lactamases
60. Carbapenemases: A problem in waiting?
61. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)
62. Peptide antibiotics
63. In vitro antibacterial activity and mechanism of action of J-111,225, a novel 1β-methylcarbapenem, against transferable IMP-1 metallo-β-lactamase producers